(C) Coriell Institute 2012 - Dr Michael ChristmanPatient-centered Precision Care
Turning research on human genotyping into healthcare routines

December 2012. What are near-term prospects of personalized medicine. In recent years genomic medicine – genetic diagnostics, biological drugs, and respective treatments – has been advancing on technological and organisational levels. However notable shortcomings persist.

While molecular technologies regularly inform routine medical decisions today, at least in larger clinical laboratories or academic health centres, there is a distinct lack of institutionalisation. In practice most applications and treatments based on genotyping continue to be labelled “for research use”. This typically translates into a legal disclaimer, falls short of educating physicians, or results in costly redundancies in healthcare. In the exclusive interview with B2Bioworld Dr Michael Christman, President of the Coriell Institute for Medical Research at Camden, New Jersey (US), talks about some tricky issues of turning research on genotyping into healthcare routines.

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 6 pages
- Includes map of Coriell's worldwide customers for cell lines, updated facts on business strategy (CoriellLogi)c, clinically actionable biomarkers, approved medical conditions for gene testing

Full Company License enquire here

Back to section

Related Editorial Articles

Diagnostic Microfluidics: Sample In – Results Out?
Marc N. Feiglin, former Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

The Myriad Way
Peter D Meldrum, at the time CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Custom Sequencing Markets
Worldwide evolution of the market and upcoming business opportunities

Metrics for Disease, Health, and Wellness
A systems look at DNA sequencing for personalized medicine by Leroy Hood, President Institute for Systems Biology, Seattle

Electrophoresis in Proteomics
Some Common Pitfalls and Smart Ways to Avoid Them

Systems Biology in Search of Good Questions
Walter Kolch on the approach taken by Systems Biology Ireland

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, past Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine